Hidradenitis Suppurativa in Patients with HIV: A Scoping Review

Macca, Laura; Moscatt, Vittoria; Ceccarelli, Manuela; Ingrasciotta, Ylenia; Nunnari, Giuseppe; Guarneri, Claudio

doi:10.3390/biomedicines10112761

Cited by 5 publications

(3 citation statements)

References 61 publications

(126 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several autoimmune and endocrine disorders have been found to be associated with HS, including inflammatory bowel disease, psoriasis, arthritis, and polycystic ovary syndrome [20][21][22][23]. Additionally, viral infections such as human immunodeficiency virus (HIV) predispose patients to develop HS with the involvement of atypical sites, such as face or thighs [24]. However, no clear association was found between HS and COVID-19 infection [25].…”

Section: Introductionmentioning

confidence: 99%

Immune Dysregulation and Current Targeted Biologics in Hidradenitis Suppurativa

Chen,

Guo,

Petty

et al. 2024

Immuno

View full text Add to dashboard Cite

Hidradenitis Suppurativa (HS) is a debilitating cutaneous disease characterized by a vicious cycle of chronic inflammation and tissue destruction that stems from disruption of the skin microbiome and abnormal activation of both the innate and adaptive immune system. A hallmark of HS pathophysiology is dysregulation of both the innate and adaptive immune system. The role of immune system dysregulation in HS development has motivated researchers to explore the utility of biologic immunomodulators. In 2015, adalimumab, a tumor necrosis factor-α inhibitor, was approved by the Food and Drug Administration (FDA) for treatment of moderate-to-severe HS in the US. In 2023, secukinumab, an interleukin-17A (IL-17A) inhibitor, was approved by the European Medicines Agency for treatment of moderate-to-severe HS in Europe. Ongoing clinical trials have shown promising clinical responses to targeted therapies against other pro-inflammatory cytokines including IL-17, IL-12, IL-1, IL-36, IL-6, IL-10, interferon γ, C5a, and Janus kinase (JAK). We provide an update on the efficacy and clinical usage of targeted biologics in HS treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Immune Dysregulation and Current Targeted Biologics in Hidradenitis Suppurativa

Chen,

Guo,

Petty

et al. 2024

Immuno

View full text Add to dashboard Cite

show abstract

“…HS comorbidities have been documented to affect multiple organ systems [ 10 , 11 , 12 , 13 ]. Although the precise pathogenesis of HS remains unknown, there is a consensus that it is a multifactorial disease involving immunological factors and the recruitment of self-perpetuating inflammatory mediators [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

New-Onset Hidradenitis Suppurativa in Psoriasis Patients: A Multi-Center, Retrospective Cohort Study

Li,

Lo,

Tsai

et al. 2024

Life

View full text Add to dashboard Cite

Background: Previous research has indicated a potential correlation between hidradenitis suppurativa (HS) and psoriasis (PSO), two chronic inflammatory dermatological diseases. However, there is a lack of comprehensive evaluations that consider a variety of clinical and demographic factors, and the risk of developing HS in PSO patients remains unclear. Our study aims to examine HS risk over time among PSO patients versus matched controls while considering the influence of confounders to provide insights into the potential link between these two diseases. Method: In this multi-institutional cohort study using the TriNetX database, we matched 202,318 patients with PSO with an equivalent number of individuals without PSO, using propensity score matching. The study period extended from 1 January 2005 to 31 December 2018. We computed hazard ratios and their respective 95% confidence intervals (CIs) to evaluate the probability of HS manifestation over a period of 5 years in patients with PSO in comparison to those without PSO. Results: PSO patients demonstrated a consistently higher risk of developing HS than matched controls across all analytic models with the hazard ratios (HR) ranging from 1.43 (95% CI 1.30–1.56) to 5.91 (95% CI 2.49–14.04). Stratified analyses showed the increased HS risk was observed in both genders but only significant in those aged 18–64 years. Kaplan–Meier analysis indicated PSO patients had a higher cumulative probability of developing HS over time (HR 1.77, 95% CI 1.49–1.89). Conclusions: PSO was associated with increased HS risk, highlighting the importance of considering HS as a potential comorbidity in PSO patients and may have implications for early detection, prevention, and management strategies for both conditions. Shared inflammatory pathways, genetic components, and skin dysbiosis may contribute. Further research should elucidate underlying mechanisms.

show abstract

“…It typically affects the intertriginous (axillary, submammary and inguinal), and anogenital areas, which later can lead to the development of abscesses, sinus tracts and scars, with devastating impact on patient's quality of life (QoL) (1). The pathogenesis of HS is not yet well understood, but there is a general agreement on considering HS as a multifactorial disease having a plenty of implications with immunological factors and recruitment of self-perpetuating inflammatory mediators, which makes HS treatment a real challenge (4). HS is known to have a substantial impact on the QoL, being also associated with various comorbidities including increased cardiovascular risk, gastrointestinal, rheumatological and psychiatric comorbidities, as well as an increased risk of carcinogenesis (5).…”

Section: Introductionmentioning

confidence: 99%

Hidradenitis suppurativa and psoriasis: the odd couple

et al. 2023

Self Cite

View full text Add to dashboard Cite

Psoriasis and hidradenitis suppurativa are chronic inflammatory skin diseases that can develop together, negatively impacting on the patient’s quality of life. We aimed to review the most up-to-date information regarding the epidemiology, pathogenesis, clinical presentation and possible therapeutical choices in patients with both psoriasis and hidradenitis suppurativa, thus linking these two autoimmune and autoinflammatory conditions. A narrative review of articles dating from 2017 to 2022 has been performed using the PubMed database. We analyzed the case reports and case series found in the literature regarding patients who suffered from both psoriasis and HS. Psoriasis arose before hidradenitis suppurativa in the majority of cases, while only a minority of them had hidradenitis suppurativa before psoriasis. Interestingly, some patients suffered from paradoxical hidradenitis suppurativa following biological therapy administered to treat the already present psoriasis. Lastly, new biological drugs have been marketed with great success for the outcome of psoriasis, but similar progress did not happen for hidradenitis. Novel therapeutic approaches and lines of research are needed for the treatment of these pathologies, even if concomitant, in order to improve patient’s quality of life.

show abstract

Hidradenitis Suppurativa in Patients with HIV: A Scoping Review

Cited by 5 publications

References 61 publications

Immune Dysregulation and Current Targeted Biologics in Hidradenitis Suppurativa

Immune Dysregulation and Current Targeted Biologics in Hidradenitis Suppurativa

New-Onset Hidradenitis Suppurativa in Psoriasis Patients: A Multi-Center, Retrospective Cohort Study

Hidradenitis suppurativa and psoriasis: the odd couple

Contact Info

Product

Resources

About